Glass House Brands (GLAS) EBITDA Margin (2020 - 2026)

Glass House Brands (GLAS) posted quarterly EBITDA Margin of 35.42% for Q1 2026, down 8.5% quarter-over-quarter from 32.64% in Q4 2025.

Glass House Brands (GLAS) EBITDA Margin (2020 - 2026) Analysis & Trends

Glass House Brands (GLAS) has reported EBITDA Margin for 7 consecutive years, with 35.42% the latest figure, recorded in Q1 2026.

In Q1 2026, EBITDA Margin changed N/A year-over-year to 35.42%; the TTM figure through Mar 2026 stood at 15.63% (changed N/A YoY), while the FY2025 annual figure was 9.08%, down 1194.0% from the prior year.
EBITDA Margin retreated to 35.42% in Q1 2026 per GLAS's latest filing, from 32.64% in the prior quarter.
Across five years, EBITDA Margin topped out at 59.28% in Q2 2022 and bottomed at 35.42% in Q1 2026.
Historically, EBITDA Margin has averaged 5.97% across 5 years, with a median of 9.01% in 2022.
Annual changes were most pronounced in 2022 — EBITDA Margin soared 7805 bps — and 2023, when it tumbled 5207 bps.
Glass House Brands' EBITDA Margin stood at 8.68% in 2022, then dropped by 17 bps to 7.22% in 2023, then gained by 30 bps to 9.35% in 2024, then slumped by 449 bps to 32.64% in 2025, then slipped by 8 bps to 35.42% in 2026.
Business Quant data shows GLAS's EBITDA Margin at 35.42% in Q1 2026, 32.64% in Q4 2025, and 29.6% in Q3 2025.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	EBITDA Margin (Qtr)
1	Haleon	43.83 Bn	42.86 Bn	-	-
2	Teva Pharmaceutical Industries	42.87 Bn	39.22 Bn	2.15 Bn	-5.58%
3	Zoetis	31.41 Bn	29.73 Bn	1.05 Bn	33.91%
4	Takeda Pharmaceutical	28.55 Bn	22.75 Bn	5.10 Bn	16.51%
5	United Therapeutics	22.08 Bn	19.42 Bn	683.80 Mn	42.23%
6	Viatris	18.73 Bn	17.84 Bn	1.46 Bn	0.17%
7	Neurocrine Biosciences	15.44 Bn	15.05 Bn	935.80 Mn	15.80%
8	Elanco Animal Health	11.75 Bn	11.22 Bn	798.00 Mn	18.13%
9	Dr Reddys Laboratories	10.11 Bn	9.94 Bn	-	-
10	Glass House Brands	837.25 Mn	818.69 Mn	15.77 Mn	-6.37%

Download Data